Pembrolizumab for the treatment of gastric cancer

Suneel D. Kamath; Aparna Kalyan; Al B. Benson

doi:10.1080/14737140.2018.1526084

Pembrolizumab for the treatment of gastric cancer

Suneel D. Kamath^*, Aparna Kalyan, Al B. Benson

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Abstract

Introduction: Gastric cancer is one of a few gastrointestinal malignancies in which immunotherapy has shown meaningful activity. Pembrolizumab is the first and only immune checkpoint inhibitor to be FDA-approved in gastric cancer. Areas Covered: This review summarizes the current and emerging clinical evidence for immune checkpoint inhibitors in advanced and metastatic gastric cancer, with a focus on pembrolizumab. Expert Commentary: Pembrolizumab has shown impressive activity in the third-line treatment of locally advanced and metastatic gastric cancer. It is currently being studied as upfront therapy in combination with chemotherapy. The emerging understanding of the molecular alterations and tumor immune microenvironment as predictors of immunotherapy response in gastric cancer are discussed. The impact of gastric mucosal dysbiosis on gastric carcinogenesis and the modulation of immunotherapy response by the gut microbiome are also reviewed.

Original language	English (US)
Pages (from-to)	1177-1187
Number of pages	11
Journal	Expert review of anticancer therapy
Volume	18
Issue number	12
DOIs	https://doi.org/10.1080/14737140.2018.1526084
State	Published - Dec 2 2018

Keywords

Gastric cancer
PD-1
PD-L1
immuno-oncology
immunotherapy
microsatellite instability
pembrolizumab

ASJC Scopus subject areas

Oncology
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/14737140.2018.1526084

Cite this

@article{756bdd8f2d6a4191aa303359e62c16d7,

title = "Pembrolizumab for the treatment of gastric cancer",

abstract = "Introduction: Gastric cancer is one of a few gastrointestinal malignancies in which immunotherapy has shown meaningful activity. Pembrolizumab is the first and only immune checkpoint inhibitor to be FDA-approved in gastric cancer. Areas Covered: This review summarizes the current and emerging clinical evidence for immune checkpoint inhibitors in advanced and metastatic gastric cancer, with a focus on pembrolizumab. Expert Commentary: Pembrolizumab has shown impressive activity in the third-line treatment of locally advanced and metastatic gastric cancer. It is currently being studied as upfront therapy in combination with chemotherapy. The emerging understanding of the molecular alterations and tumor immune microenvironment as predictors of immunotherapy response in gastric cancer are discussed. The impact of gastric mucosal dysbiosis on gastric carcinogenesis and the modulation of immunotherapy response by the gut microbiome are also reviewed.",

keywords = "Gastric cancer, PD-1, PD-L1, immuno-oncology, immunotherapy, microsatellite instability, pembrolizumab",

author = "Kamath, {Suneel D.} and Aparna Kalyan and Benson, {Al B.}",

note = "Funding Information: AB Benson has acted in a consulting or advisory role for Genentech/Roche, Bristol-Myers Squibb, Novartis, Celgene, Pfizer and AstraZeneca; has received fees for travel, accommodations and expenses from Genentech/ Roche, Bristol-Myers Squibb and Sanofi, and has received research funding from Novartis, Bristol-Myers Squibb, Merck Sharp & Dohme, Celgene and MedImmune. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Publisher Copyright: {\textcopyright} 2018, {\textcopyright} 2018 Informa UK Limited, trading as Taylor & Francis Group.",

year = "2018",

month = dec,

day = "2",

doi = "10.1080/14737140.2018.1526084",

language = "English (US)",

volume = "18",

pages = "1177--1187",

journal = "Expert Review of Anticancer Therapy",

issn = "1473-7140",

publisher = "Expert Reviews Ltd.",

number = "12",

}

TY - JOUR

T1 - Pembrolizumab for the treatment of gastric cancer

AU - Kamath, Suneel D.

AU - Kalyan, Aparna

AU - Benson, Al B.

N1 - Funding Information: AB Benson has acted in a consulting or advisory role for Genentech/Roche, Bristol-Myers Squibb, Novartis, Celgene, Pfizer and AstraZeneca; has received fees for travel, accommodations and expenses from Genentech/ Roche, Bristol-Myers Squibb and Sanofi, and has received research funding from Novartis, Bristol-Myers Squibb, Merck Sharp & Dohme, Celgene and MedImmune. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Publisher Copyright: © 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group.

PY - 2018/12/2

Y1 - 2018/12/2

N2 - Introduction: Gastric cancer is one of a few gastrointestinal malignancies in which immunotherapy has shown meaningful activity. Pembrolizumab is the first and only immune checkpoint inhibitor to be FDA-approved in gastric cancer. Areas Covered: This review summarizes the current and emerging clinical evidence for immune checkpoint inhibitors in advanced and metastatic gastric cancer, with a focus on pembrolizumab. Expert Commentary: Pembrolizumab has shown impressive activity in the third-line treatment of locally advanced and metastatic gastric cancer. It is currently being studied as upfront therapy in combination with chemotherapy. The emerging understanding of the molecular alterations and tumor immune microenvironment as predictors of immunotherapy response in gastric cancer are discussed. The impact of gastric mucosal dysbiosis on gastric carcinogenesis and the modulation of immunotherapy response by the gut microbiome are also reviewed.

AB - Introduction: Gastric cancer is one of a few gastrointestinal malignancies in which immunotherapy has shown meaningful activity. Pembrolizumab is the first and only immune checkpoint inhibitor to be FDA-approved in gastric cancer. Areas Covered: This review summarizes the current and emerging clinical evidence for immune checkpoint inhibitors in advanced and metastatic gastric cancer, with a focus on pembrolizumab. Expert Commentary: Pembrolizumab has shown impressive activity in the third-line treatment of locally advanced and metastatic gastric cancer. It is currently being studied as upfront therapy in combination with chemotherapy. The emerging understanding of the molecular alterations and tumor immune microenvironment as predictors of immunotherapy response in gastric cancer are discussed. The impact of gastric mucosal dysbiosis on gastric carcinogenesis and the modulation of immunotherapy response by the gut microbiome are also reviewed.

KW - Gastric cancer

KW - PD-1

KW - PD-L1

KW - immuno-oncology

KW - immunotherapy

KW - microsatellite instability

KW - pembrolizumab

UR - http://www.scopus.com/inward/record.url?scp=85054390956&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054390956&partnerID=8YFLogxK

U2 - 10.1080/14737140.2018.1526084

DO - 10.1080/14737140.2018.1526084

M3 - Article

C2 - 30280940

AN - SCOPUS:85054390956

VL - 18

SP - 1177

EP - 1187

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 12

ER -

Pembrolizumab for the treatment of gastric cancer

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this